Tirzepatide – Dual GIP and GLP-1 Receptor Agonist Therapy

Tirzepatide is an innovative medicinal substance representing the world's first dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The drug is a synthetic peptide that mimics the action of natural incretins, providing a comprehensive approach to treating metabolic disorders. Tirzepatide demonstrates unprecedented efficacy in lowering blood sugar levels and significant reduction in body weight.

The mechanism of action of tirzepatide is based on the synergy of two hormones. As a GIP agonist, it improves insulin secretion and sensitivity while positively affecting lipid metabolism. As a GLP-1 agonist, the drug slows gastric emptying and acts on satiety centers in the brain, reducing appetite and food intake. Simultaneous activation of these receptors allows for more potent glycemic control compared to selective GLP-1 agonists. Additionally, tirzepatide favorably influences cardiovascular markers and liver health in fatty hepatosis. The drug has a long half-life, allowing for once-weekly administration.

Tirzepatide is intended for subcutaneous administration and is a vital tool in the therapy of patients with diabetes and obesity.

Wikipedia page
Tirzepatide

Indications

Tirzepatide is indicated for use in adult patients for the following clinical conditions:

  • Type 2 Diabetes Mellitus: as an adjunct to diet and exercise to improve glycemic control in monotherapy or in combination with other agents.
  • Weight Management: long-term weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) in the presence of weight-related comorbidities.
  • Cardiovascular Prevention: reduction of risk for complications associated with metabolic disorders and high body mass index.
  • Metabolic Disorders: improvement of insulin sensitivity and correction of dyslipidemia in patients with metabolic syndrome.

Dosage and administration

Tirzepatide therapy requires gradual dose titration to minimize gastrointestinal side effects.

  • Initial Dose: treatment begins with 2.5 mg subcutaneously once weekly for the first 4 weeks.
  • Titration: after 4 weeks, the dose is increased to 5 mg once weekly. If further control is needed, the dose is increased in 2.5 mg increments every 4 weeks.
  • Maximum Dose: the maximum allowable dosage is 15 mg once weekly.
  • Administration Method: the drug is injected subcutaneously in the abdomen, thigh, or upper arm at any time of day, regardless of meals.
  • Missed Dose: if a dose is missed, it can be taken within 4 days after the scheduled date.

The use of tirzepatide is contraindicated in the presence of certain hereditary risks and conditions:

  • Medullary Thyroid Carcinoma: personal or family history of medullary thyroid carcinoma (MTC).
  • MEN 2 Syndrome: Multiple Endocrine Neoplasia syndrome type 2.
  • Hypersensitivity: serious allergic reactions to tirzepatide or any of the product's components.
  • Pregnancy and Lactation: use of the drug is not recommended; treatment should be discontinued at least 2 months before planned conception.
  • Severe GI Disease: the drug is not recommended for patients with severe gastroparesis or active inflammatory bowel disease.

The most common side effects are related to the adaptation of the digestive system to the drug's action:

  • Gastrointestinal Tract: nausea, vomiting, diarrhea, constipation, and epigastric discomfort, which usually diminish over time.
  • Decreased Appetite: a pronounced sense of fullness, which is a therapeutic effect but may be excessive at the start of the course.
  • Local Reactions: redness, itching, or swelling at the injection site.
  • Pancreas: rare cases of acute pancreatitis have been reported.
  • Gallbladder: increased risk of cholelithiasis (gallstones) during rapid weight loss.
  • Hypoglycemia: the risk of significant blood sugar reduction increases only when combined with sulfonylureas or insulin.

Frequently Asked Questions

Tirzepatide is a first-in-class medication that simultaneously activates two hormone receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones, naturally produced in the gut, regulate insulin secretion, satiety, and fat metabolism. By targeting both receptors, tirzepatide provides more potent blood sugar control and weight loss results compared to previous single-hormone therapies.
Clinical trials have demonstrated that tirzepatide effectively lowers glycated hemoglobin (HbA1c) to target levels in the majority of patients. Furthermore, the substance shows remarkable efficacy in body weight reduction: depending on the dose and treatment duration, patients can lose between 15% and 22% of their initial body weight when combined with diet and exercise.
Tirzepatide is administered as a subcutaneous injection (into the abdomen, thigh, or upper arm) once weekly. Therapy always begins at a low starting dose (e.g., 2.5 mg) for the first 4 weeks. This gradual titration allows the body to adjust to the medication and helps minimize gastrointestinal side effects. Every 4 weeks, the dose may be increased by a physician until the optimal therapeutic target is reached.
The most common reactions include nausea, diarrhea, decreased appetite, and vomiting. These symptoms are typically mild to moderate and occur most frequently during the first few days after an injection or following a dose increase; they usually subside over time. To manage these effects, it is recommended to eat smaller meals, avoid greasy foods, and stay well-hydrated.
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If you notice a lump or swelling in the neck, hoarseness, or difficulty swallowing, you should consult an endocrinologist immediately.

List of medicines by active substance

-14%
Mounjaro KwikPen 12.5 12.5 mg Eli Lilly
View
Eli Lilly

Mounjaro KwikPen 12.5

Tirzepatide
12.5 mg 1 pen
19506₴ 22787₴
-11%
Mounjaro KwikPen 10 10 mg Eli Lilly
View
Eli Lilly

Mounjaro KwikPen 10

Tirzepatide
10 mg 1 pen
18472₴ 20764₴
-8%
Mounjaro KwikPen 7.5 7.5 mg Eli Lilly
View
Eli Lilly

Mounjaro KwikPen 7.5

Tirzepatide
7.5 mg 1 pen
17438₴ 18921₴
-5%
Mounjaro KwikPen 5 5 mg Eli Lilly
View
Eli Lilly

Mounjaro KwikPen 5

Tirzepatide
5 mg 1 pen
15955₴ 16764₴
-11%
Mounjaro KwikPen 2.5 2.5 mg Eli Lilly
View
Eli Lilly

Mounjaro KwikPen 2.5

Tirzepatide
2.5 mg 1 pen
12899₴ 14472₴
-8%
Mounjaro KwikPen 15 15 mg Eli Lilly
View
Eli Lilly

Mounjaro KwikPen 15

Tirzepatide
15 mg 1 pen
21888₴ 23685₴
-11%
Mounjaro 5 5 mg / 0.5 ml Eli Lilly
View
Eli Lilly

Mounjaro 5

Tirzepatide
5 mg / 0.5 ml 1 vial
4000₴ 4494₴
-15%
Mounjaro 2.5 2.5 mg / 0.5 ml Eli Lilly
View
Eli Lilly

Mounjaro 2.5

Tirzepatide
2.5 mg / 0.5 ml 1 vial
3236₴ 3820₴
✅ All products loaded (8)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00